Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium.

Trial Profile

Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2012

At a glance

  • Drugs Choline fenofibrate; Rosuvastatin; Rosuvastatin/choline fenofibrate
  • Indications Acute coronary syndromes; Cardiovascular disorders; Heart failure; Hyperlipidaemia; Kidney disorders; Myocardial infarction; Stroke
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 20 Sep 2012 Disease descriptors added
    • 22 Jan 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Dec 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top